Drug Profile
Research programme: VEGF-targeted vaccines - Protherics
Latest Information Update: 17 Jul 2007
Price :
$50
*
At a glance
- Originator Protherics
- Class
- Mechanism of Action Immunostimulants; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer metastases
Most Recent Events
- 02 Oct 2001 Preclinical development for Cancer metastases in United Kingdom (unspecified route)